BioTrinity 2008 - Oxford today announces a highly relevant new addition to its programme. Oxfordshire Bioscience Networks' leading partnering and networking event confirmed that Peter Nolan, SVP Commercial Development at Oxford BioMedica, will discuss the company's deal with sanofi-aventis to develop and commercialise TroVax® for the treatment and prevention of cancers. This follows the announcement that the TRIST trial successfully completed patient enrolment.
Oxford, United Kingdom (PRWEB) March 18, 2008 -- BioTrinity 2008 - Oxford today announces a highly relevant new addition to its programme. Oxfordshire Bioscience Networks' leading partnering and networking event confirmed that Peter Nolan, SVP Commercial Development at Oxford BioMedica, will discuss the company's deal with sanofi-aventis to develop and commercialise TroVax® for the treatment and prevention of cancers. This follows the announcement that the TRIST trial successfully completed patient enrolment.
Photograph of networking at BioTrinity 2008
TroVax® is Oxford BioMedica's lead cancer immunotherapy. Based on the broad distribution of the 5T4 tumour antigen, TroVax® has potential application in a wide range of solid tumours, including renal, colorectal, lung, breast and prostate cancer. Earlier this month Oxford BioMedica announced that it has successfully completed patient enrolment in the Phase III TRIST study.
Over 690 patients have been randomised to-date and a sufficient number of additional patients are being screened for inclusion such that the total enrolment is expected to slightly exceed the target of 700 patients. Over 100 sites in the USA, European Union and Eastern Europe have recruited patients into the trial. The trial started in November 2006; recruitment has been completed on schedule and final results from the study are anticipated in the first half of 2009.
Peter Nolan commented "I am delighted to be speaking at BioTrinity 2008, which is an opportune platform on which we can discuss the recent milestones achieved in the development of TroVax, our lead cancer immunotherapy."
BioTrinity 2008 is taking place on April 15-16, 2008 in Oxford, UK and provides the opportunity to view the latest presentations from the most promising companies within the UK's most successful biotech super-cluster in Oxford and the South East of England.
More conference details are available online at http://www.biotrinity.com.
Register now to receive your complimentary press pass:
De Facto Communications
Gemma Ryan
Tel: +44 (0) 20 7861 3838
g.ryan @ defacto.com
Notes to Editors:
BioTrinity 2008, April 15-16, 2008, Oxford, is the country's leading biotech partnering event. It will showcase the Oxford & South East UK's biotechnology super cluster, which leads the UK in attracting investment. Twenty-five of the most promising drug discovery and development, diagnostics and medical device companies have been selected to be featured in BioTrinity's "Most Promising Emerging Company Showcase" and "Clinical Stage Developments" featuring the region's drug pipeline. There are also: one-to-one partnering meetings, a licensing and spin-out technology showcase, an exhibition and a number of workshops. More conference details are available online at www.biotrinity.com.
OBN is the South East's leading biotech business network, catalysing the growth and development of the Oxford and the South East biotech and healthcare biotech super-cluster. Launched by Lord Sainsbury in 1999, OBN is a financially self-sustainable network which raises 95% of its operating costs from private sources and operational activity including a lab supplies purchasing scheme, as well as membership. In the past 8 years, OBN has delivered over 90 meetings, attracting thousands of delegates, most notably its trademark BioTuesday biotech business networking evenings and BioTrinity, its annual partnering conference. More information is available online at www.oxfordshirebioscience.com.
###
Trackback URL: http://www.prweb.com/pingpr.php/WmV0YS1UaGlyLUhvcnItQ3Jhcy1Ib3JyLVplcm8=
|
